Objective This study aimed to evaluate the clinical efficacy of belimumab in patients with
early systemic lupus erythematosus (SLE), defined as having a disease duration of less than …

Background The increasing administration of belimumab has demonstrated its biological
benefits. Prior meta-analyses have examined the overall adverse events (AEs) associated …

Introduction We have been conducting an evaluation of innovative therapies in patients with
SLE during the past 15 years. We combine the results observed on extension studies from …

Objective To examine the effects of belimumab initiation on healthcare resource utilisation
(HCRU) and costs in SLE. Methods This retrospective observational cohort study used …

Objective: To investigate the effectiveness and safety of belimumab in patients with active
systemic lupus erythematosus (SLE) in a real-life setting. Methods: All SLE patients treated …

Objective To examine the long-term changes in circulating B cell subsets and IgG levels at
5+ years of continuous belimumab treatment and their correlations with efficacy and safety …

Systemic lupus erythematosus (SLE) is a complex heterogeneous disease, posing
challenges to clinical trials. As in other autoimmune diseases, B-lymphocytes play a central …

Purpose The goal of this study was to evaluate clinical and economic outcomes associated
with the initiation of intravenous (IV) belimumab for the treatment of systemic lupus …

Objective To examine long-term organ damage and safety following treatment with
belimumab plus standard of care (SoC) in patients with systemic lupus erythematosus (SLE) …

Abstract Introduction and objectives This OBSErve Spain study, a part of the international
OBSErve programme, evaluated belimumab real-world use and effectiveness following 6 …